@article{90633192f24d400c8322e75cda693458,
title = "Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study",
keywords = "anti-pd-1 antibody, anti-pd-1 therapy, brain metastases, combined nivolumab, competing risks, immunotherapy, ipilimumab, lactate-dehydrogenase, metastatic melanoma, multicenter, nivolumab, open-label, pembrolizumab, population-based, real-world, survival, LACTATE-DEHYDROGENASE, SURVIVAL, anti-PD-1 antibody, METASTATIC MELANOMA, BRAIN METASTASES, anti-PD-1 therapy, MULTICENTER, COMBINED NIVOLUMAB, OPEN-LABEL, PEMBROLIZUMAB, IMMUNOTHERAPY, IPILIMUMAB",
author = "{van Zeijl}, M.C.T. and J.B.A.G. Haanen and M.W.J.M. Wouters and {de Wreede}, L.C. and A. Jochems and M.J.B. Aarts and {van den Berkmortel}, F.W.P.J. and {de Groot}, J.W.B. and G.A.P. Hospers and E.W. Kapiteijn and D. Piersma and {van Rijn}, R.S. and K.P.M. Suijkerbuijk and {ten Tije}, A.J. and {van der Veldt}, A.A.M. and G. Vreugdenhil and {van der Hoeven}, K.J.M. and {van den Eertwegh}, A.J.M.",
year = "2020",
month = oct,
day = "1",
doi = "10.1097/CJI.0000000000000334",
language = "English",
volume = "43",
pages = "256--264",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "8",
}